--2025/Q1-- / 79.926B--
--2024/Q4-- / 81.424B--
May 2, 20242024/Q165.349B / 63.573B--
US Stock MarketDetailed Quotes
NVO Novo-Nordisk A/S
- 102.760
- -2.510-2.38%
Trading Nov 21 09:33 ET
457.91BMarket Cap34.29P/E (TTM)
103.160High102.760Low165.81KVolume103.150Open105.270Pre Close17.04MTurnover0.01%Turnover Ratio39.04P/E (Static)4.46BShares147.59352wk High26.88P/B327.79BFloat Cap93.69952wk Low1.48Dividend TTM3.19BShs Float147.593Historical High1.44%Div YieldTTM0.38%Amplitude-3.073Historical Low102.792Avg Price1Lot Size
Novo-Nordisk A/S Key Stats
Novo-Nordisk A/S Q3 2024 Earnings Date
Highlights | Sales of the Q3 diet drug Wegovy surged, and operating profit increased 26%! Sales are expected to grow 23% to 27% for the full year of 2024
Currency：DKKNov 6, 2024
| Estimate (YoY) | Actual (YoY) | Vs Estimate (% Chg) | |
| Revenue | 71.87B | 71.31B | -558.36M |
| Miss Est. | +22.37% | +21.42% | -0.78% |
| EPS | 5.95 | 6.12 | +0.17 |
| Beat Est. | +19.03% | +22.40% | +2.83% |
Analyst Rating
Nov 11, 2024
Novo-Nordisk A/S Earnings Estimates
Revenue
EPS
EBIT
Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement
Currency: DKK
Actual
Estimate
Unlock Free Earnings Estimates
Open Account
Novo-Nordisk A/S Earnings Reports
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
